Fusion Pharmaceuticals Inc expected to post a loss of 48  cents a share - Earnings Preview

Fusion Pharmaceuticals

06/05/2022 19:31

* Fusion Pharmaceuticals Inc  FUSN.OQ   FUSN.O  is expected
to show a rise in quarterly revenue when it reports  results on
May 9 (estimated). 
    * The Hamilton Ontario Ontario-based  company is expected to
report revenue of $1.125 million, according to the mean estimate
from 4 analysts, based on Refinitiv data.  
    * ​Refinitiv's mean analyst estimate for Fusion
Pharmaceuticals
Inc is for a loss of 48 cents per share. For the same quarter
last year, the company reported a loss of 42 cents per share.
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 6 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell."  
    * The mean earnings estimate of analysts was unchanged in
the last
three months. ​
    * Wall Street's median 12-month price target for Fusion
Pharmaceuticals Inc is $19​, above​ its last closing price
of $4.90. ​​​
    * Previous quarterly performance (using preferred earnings
measure
in US dollars). ​

 QUARTER       STARMINESM  REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        ARTESTIMAT  IBES                 MET,    SE %
               E®          ESTIMATE             MISSED  
 Dec. 31 2021  -0.42       -0.47      -0.40     Beat    14.3
 Sep. 30 2021  -0.61       -0.60      -0.45     Beat    24.7
 Jun. 30 2021  -0.43       -0.39      -0.63     Missed  -61.5​
 Mar. 31 2021  -0.30       -0.29      -0.42     Missed  -43.2
 ​​Dec.        -0.19       -0.19      -0.32     Missed  -66.2
 31 2020                                                
 Sep. 30 2020  -0.14       -0.14      -0.24     Missed  -71.4​
 Jun. 30 2020  -0.50       -0.50      -2.99     Missed  -498
 This summary was machine generated May 6 at 18:31 GMT.  All
figures in US dollars  unless otherwise stated